Microsoft word - cv dsb.doc

Debra Schwab Brandt, D.O.
Northwestern Connecticut Oncology/Hematology Associates, LLP 200 Kennedy Drive New Milford Cancer Center
Sharon, CT 06069 Torrington, CT 06790 21 Elm St, New Milford, CT 06776
Specialties - Medical Hematology and Medical Oncology and Internal Medicine
1998 - present
Private Practice- Northwest Connecticut Oncology/Hematology Associates Director of Clinical Trials - Responsible for Overseeing Clinical Trials
Hospital Privledges - Charlotte Hungerford Hospital, New Milford Hospital,

Postdoctoral Training
Fellowship: Yale University- New Haven, Connecticut
7/95 - 6/98 Hematology/Oncology Department
Residency: UMDNU-Robert Wood Johnson University Hospital-New Brunswick, N.J/
7/93 - 6/95 Internal Medicine Department
Residency: Beth Israel Medical Center-New York, N.Y.
7/92 - 6/93 Internal Medicine Department
Internship: Union Hospital-Rotating Internship-Union, N.J. 7/91-6/91 Education
Board Certification: Osteopathic National Boards 1991 Internal Medicine 1995 Medical Debra Schwab Brandt, D.O.
Northwestern Connecticut Oncology/Hematology Associates, LLP ______________________________________________________________________ Honors and Awards
Sigma Sigma Phi - National Honor and Service Society.
Ram’s Head Award - Expertise in Osteopathic manipulation
Connecticut Magazine: Best Doctor in Connecticut Award as Chosen by Peers 2004


1) Research Director at NW Oncology/Hematology Associates. Participate in ECOG,
Yale Oncology Network, and pharmaceutical company driven protocols. 2) Laboratory Experience: One year exploring the biochemical mechanism for synergistic activity between fludarabine and cyclophosphamide (with Dr. Ed Chu- Yale University). 3) Clinical Protocol Investigator: Phase II trial of cytoxan, vincristine, and fludarabine in patients with CLL and primary and refractory low grade non-hodgkin’s lymphoma.
1) Salloum, E., Brandt, D., CarideE., et al.: Gallium Scans in the Management of
Patients with Hodgkin’s Disease: A Study of 101 Patients: JCO 15, 518-527, 1997. 2) Brandt, D. and Chu, E.: Future Challenges in the Clinical Development of Thymidylate Synthase Inhibitor Compounds, Onc. Res. 9: 403-410, 1998. 3) Brandt, D. and Chu, E.: The development of the TS Inhibitor Compounds in the treatment of human colorectal cancer., Advances in Colon Cancer, 10, 1997. 4) Brandt, D. and Chu, E.: Rescue agents for 5-fluorouracil., Advances in Colon 5) Fischer, D.S., Knobf, T.M. and Durivage, H.J.: The Cancer Chemotherapy Handbook,. Mosby Yearbook Inc. 1997. Aided in the research and writing of the chapter on combination chemotherapy.
2002-present: Transfusion Committee-chair
1999-present: Institutional Review Board
1999-present: Pharmacy and Therapeutics Committee
1998-present: Cancer Committee
2000-present: Programming Committee
ASCO, AMA, AOA, ASH, Connecticut Oncology Associates, ECOG, Yale Oncology



Preferences in Game Logics Abstract even excluding the possibility that an agent might value op-tions equally. Models of social procedures that do not re- We introduce a Game Logic with Preferences ( GLP ), quire one to completely specify the preferences of agents which makes it possible to reason about how information are thus highly desirable. Gal and Pfeffer [9, 10] have also or as


Viewpoint WHO, the Global Fund, and medical malpractice in malaria Amir Attaran, Karen I Barnes, Christopher Curtis, Umberto d’Alessandro, Caterina I Fanello, Mary R Galinski, Gilbert Kokwaro, Sornchai Looareesuwan, Michael Makanga, Theonest K Mutabingwa, Ambrose Talisuna, Jean François Trape, William M Watkins In 1998, WHO launched a new, high profile campaign todoubled childhood ma

Copyright © 2014 Medical Pdf Articles